CD4 and neoplasm: Similarly, MRTX849 treatment decreased intratumoural immunosuppressive myeloid-derived suppressor cells and M2-polarised macrophages and increased immune-promoting M1-polarised macrophages, dendritic cells, and CD4 + and NKT cells in KRAS (G12C) tumours by altering the expression of tumour RNA and protein implicated in the presentation of tumour antigens or mediating an immunosuppressive TME204.